Outcomes of Extracorporeal Membrane Oxygenation (ECMO) for COVID-19 Patients: A Multi-Institutional Analysis.
COVID-19
ECMO
mechanical ventilation
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
01 Jan 2023
01 Jan 2023
Historique:
received:
22
11
2022
revised:
18
12
2022
accepted:
30
12
2022
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
In March 2020, COVID-19 was announced as a global pandemic. The first COVID-19 patient was connected to an ECMO device in Israel during that time. Since then, over 200 patients have required ECMO support due to COVID-19 infection. The present study is a multi-institutional analysis of all COVID-19 patients requiring veno-venous (VV) ECMO in Israel. The aim was to characterize and compare the survivors and deceased patients as well as establish risk factors for mortality. This retrospective multi-institutional study was conducted from March 2020 to March 2021 in eleven of twelve ECMO centers operating in Israel. All COVID-19 patients on VV ECMO support were included in the cohort. The patients were analyzed based on their comorbidities, procedural data, adverse event on ECMO, and outcomes. Univariate and multivariate analyses were used to compare the deceased and the surviving patients. The study included 197 patients, of which 150 (76%) were males, and the mean age was 50.7 ± 12 years. Overall mortality was 106 (54%). Compared with the deceased subjects, survivors were significantly younger (48 ± 11 vs. 53 ± 12 years), suffered less from ischemic heart disease (IHD) (3% vs. 12%), and were ventilated for a significantly shorter period (≤4 days) prior to cannulation (77% vs. 63%). Patients in the deceased group experienced more kidney failure and sepsis. Rates of other complications were comparable between groups. Based on this study, we conclude that early cannulation (≤4 days) of younger patients (≤55 years) may improve overall survival and that a history of IHD might indicate a reduced prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
In March 2020, COVID-19 was announced as a global pandemic. The first COVID-19 patient was connected to an ECMO device in Israel during that time. Since then, over 200 patients have required ECMO support due to COVID-19 infection. The present study is a multi-institutional analysis of all COVID-19 patients requiring veno-venous (VV) ECMO in Israel. The aim was to characterize and compare the survivors and deceased patients as well as establish risk factors for mortality.
METHODS
METHODS
This retrospective multi-institutional study was conducted from March 2020 to March 2021 in eleven of twelve ECMO centers operating in Israel. All COVID-19 patients on VV ECMO support were included in the cohort. The patients were analyzed based on their comorbidities, procedural data, adverse event on ECMO, and outcomes. Univariate and multivariate analyses were used to compare the deceased and the surviving patients.
RESULTS
RESULTS
The study included 197 patients, of which 150 (76%) were males, and the mean age was 50.7 ± 12 years. Overall mortality was 106 (54%). Compared with the deceased subjects, survivors were significantly younger (48 ± 11 vs. 53 ± 12 years), suffered less from ischemic heart disease (IHD) (3% vs. 12%), and were ventilated for a significantly shorter period (≤4 days) prior to cannulation (77% vs. 63%). Patients in the deceased group experienced more kidney failure and sepsis. Rates of other complications were comparable between groups.
CONCLUSIONS
CONCLUSIONS
Based on this study, we conclude that early cannulation (≤4 days) of younger patients (≤55 years) may improve overall survival and that a history of IHD might indicate a reduced prognosis.
Identifiants
pubmed: 36679953
pii: vaccines11010108
doi: 10.3390/vaccines11010108
pmc: PMC9865577
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Thorac Dis. 2018 Mar;10(Suppl 5):S661-S669
pubmed: 29732184
Artif Organs. 2022 Mar;46(3):349-361
pubmed: 34494291
ASAIO J. 2020 May;66(5):472-474
pubmed: 32243267
J Cardiothorac Vasc Anesth. 2022 Aug;36(8 Pt A):2700-2706
pubmed: 34906383
J Cardiothorac Vasc Anesth. 2021 Apr;35(4):1149-1153
pubmed: 32660924
J Cardiothorac Vasc Anesth. 2021 Aug;35(8):2467-2470
pubmed: 33262038
Pan Afr Med J. 2020 Aug 10;35(Suppl 2):141
pubmed: 33193956
ASAIO J. 2020 Jul;66(7):707-721
pubmed: 32604322
Crit Care. 2021 Jun 14;25(1):211
pubmed: 34127027
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Int J Artif Organs. 2022 Feb;45(2):239-242
pubmed: 33506708
Ann Thorac Surg. 2022 May;113(5):1452-1460
pubmed: 34242641
Crit Care Explor. 2021 Jun 03;3(6):e0454
pubmed: 34104895
Crit Care. 2019 Dec 23;23(1):418
pubmed: 31870400
Crit Care. 2020 May 8;24(1):205
pubmed: 32384917
N Engl J Med. 2018 May 24;378(21):1965-1975
pubmed: 29791822
Indian J Thorac Cardiovasc Surg. 2021 Apr;37(Suppl 2):309-318
pubmed: 33487891
J Card Surg. 2020 Oct;35(10):2679-2687
pubmed: 32717771
World J Clin Cases. 2021 Jul 26;9(21):5963-5971
pubmed: 34368315
ASAIO J. 2020 Aug;66(8):844-846
pubmed: 32740341
BMC Pulm Med. 2019 Dec 9;19(1):237
pubmed: 31818300
J Card Surg. 2020 Oct;35(10):2838-2843
pubmed: 32678961
Lancet Respir Med. 2022 Nov 16;:
pubmed: 36402148
Physiol Rep. 2021 Feb;9(3):e14715
pubmed: 33527751
Lancet Respir Med. 2020 Nov;8(11):1121-1131
pubmed: 32798468